Sathgen Therapeutics
New Frontiers in Oncology
At Sathgen, we are dedicated to developing breakthrough therapies that address unmet medical needs and improve patient outcomes worldwide.
Who We Are
Sathgen Therapeutics is a clinical-stage biotech division of Godavari Biorefineries. We are working on bringing first-in-class and best-in-class drugs ensuring novel treatments for difficult-to-treat cancers and potentially viral infections.
Our Trajectory
Our lead drug candidate is in phase I clinical trials in patients with advanced solid tumors as well as in healthy individuals – to evaluate safety, tolerability and pharmacokinetics of the drug.
Initiation of phase I trials
Initiation of phase I trials of MSP008-22 in patients with advanced solid tumors.
Initiation of phase I trials
Initiation of phase I trials of MSP008-22 in healthy individuals.
First Cohort Completion
Completion of the dosing of the first cohort of patients in the phase I clinical trial of MSP008-22.
Ongoing Studies
Completed Phase 1 Safety and Efficacy studies. SAD and MAD completed.
Triple Negative Breast Cancer
Xenograft studies with triple negative breast cancer cells show tumor growth inhibition upon single arm MSP008-22 or in combination with standard-of-care chemotherapy, Carboplatin.
Cisplatin Combination
MSP008-22 improves the efficacy and lowers toxicity of another standard-of-care chemotherapy, Cisplatin, as shown by decreased IC50.
Safety Profile
MSP008-22 shows excellent safety profile in pre-clinical models including induced human blood lymphocytes.
Anti-Stem Cell & Anti-Metastatic
MSP008-22 also shows anti-stem cell and anti-metastatic efficacy in breast and prostate cancer models, in vitro.
SARS-CoV-2 Treatment
Treatment with MSP008-22, both post-infection or prophylactic, reduces the SARS-CoV-2 viral load, and COVID-19-associated Pneumonitis, alveolar injury, and inflammation score.
Viral Replication Inhibition
MSP008-22 inhibits viral replication to the same extent as the anti-viral, Remdesivir.
Anti-SARS-CoV-2 Potential
MSP008-22 shows anti-SARS-CoV-2 potential as observed in cytopathic assays, comparable to Remdesivir.
About Sathgen Therapeutics
Pioneering the future of medicine through cutting-edge research and development
Research Excellence
Our world-class research team combines deep scientific expertise with innovative approaches to drug discovery.
Patient-Focused
Every breakthrough we pursue is driven by our commitment to improving the lives of patients and their families.
Global Impact
We collaborate with leading institutions worldwide to accelerate the development of life-changing therapies.
Our Pipeline
With a Pipeline of more than 40 Oncology Compounds, we are building a Diversified Portfolio aimed at addressing Critical Unmet Needs in Cancer Treatment.
Our Lead Program
Our lead program targets Triple Negative Breast Cancer (TNBC) — an aggressive and underserved cancer subtype affecting over 340,000 patients globally each year. Limited therapeutic options contribute to poor prognosis and nearly 200,000 annual deaths worldwide.
Global Patents
Comprehensive patent protection across multiple jurisdictions
MSP008-22 Anti-Cancer Compound
Granted in: USA and Japan
Synthesis of Cleistanthin A
Granted in: India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.
Process for Synthesis of Cleistanthin
Granted in: India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa
Partner with Us
We are actively advancing MSP008-22 toward clinical development and welcome strategic partnerships to accelerate its path to market.
Join our journey as we discover novel and effective treatments for hard to cure cancers.
Licensing Agreements
Regional or global licensing opportunities for MSP008-22 and pipeline compounds
Co-Development
Joint development programs with shared investment and risk mitigation strategies
Strategic Investment
Equity partnerships with pharmaceutical and biotech companies for mutual growth
Research Collaboration
Academic and industry partnerships for advancing novel therapeutic approaches
Why Godavari
Lead Compound
Demonstrated in vitro and in vivo efficacy against triple-negative breast cancer and prostate cancer.
Strong Backing
Opportunity to contribute to significant advancements in cancer treatment with potential for financial returns.
Robust Pipeline
Over 40 preclinical compounds targeting a diverse range of cancers. One compound in Phase 1
Impactful Investment
Opportunity to contribute to significant advancements in cancer treatment with potential for financial returns.
Strategic Partnerships
Strategic partnerships are central to our growth. We invite pharmaceutical companies and research organizations to collaborate with us in advancing our therapeutic programs. Whether through licensing agreements, co-development initiatives, or other partnership models, we are eager to work with visionary partners who share our goal of transforming cancer care.